• Sumatriptan Succinate: 5-HT1 Receptor Agonist

  2026-08-14

  Sumatriptan Succinate is a selective 5-HT1 receptor agonist used for acute migraine research and treatment. Its validated 5-HT1B/1D pharmacology is complemented by updated evidence that both MAO A and selected CYP enzymes participate in its metabolism.

• Berberine Hydrochloride: Assay Design

  2026-08-14

  Berberine hydrochloride connects AMPK-centered metabolic assays with gut–bone and osteoimmune research. This article presents a causal, assay-first framework for separating direct cellular effects from microbiome-mediated outcomes and selecting controls for translational studies.

• Sumatriptan: Receptor Selectivity and Metabolism

  2026-08-13

  Sumatriptan Succinate is more than a standard 5-HT1 receptor agonist: its receptor pharmacology and unexpectedly layered metabolism can reshape assay design. This guide connects 5-HT1B/1D signaling, CGRP biology, inflammation models, and metabolite-aware experimental controls.

• Phosphatase Inhibitor Cocktail 2: Workflow Guide

  2026-08-13

  Protect phosphorylation-dependent biology from lysis through Western blotting, co-immunoprecipitation, pull-down, and kinase assays with a practical 100X workflow. This guide combines broad phosphatase control with low-temperature, rationally simplified assay design inspired by recent DT-TRAP findings.

• ASCH Proteins and N4-Acetylcytidine Processing

  2026-08-12

  Meng et al. define how the E. coli ASCH-domain protein EcYqfB hydrolyzes free N4-acetylcytidine while showing that it does not remove ac4C from RNA. Structural comparisons with mouse EOLA1 and the human TRIP4-ASCH domain reveal divergent substrate preferences, providing a framework for interpreting ASCH proteins in RNA metabolism and nucleotide processing.

• (-)-JQ1: A Rigorous BET Control Workflow

  2026-08-12

  (-)-JQ1 is an inactive JQ1 stereoisomer designed to separate BET bromodomain-dependent effects from vehicle, scaffold, and off-target responses. This practical workflow shows how to pair it with active JQ1, reporter assays, and cell-to-animal screening strategies for more defensible epigenetics and cancer biology research.

• Netarsudil: From ROCK Biology to Assay Design

  2026-08-11

  Netarsudil (AR-13324) is more than a ROCK inhibitor: it is a useful model for connecting cytoskeletal pharmacology with rational siRNA formulation. This article presents a decision-oriented framework for interpreting trabecular meshwork assays, nanoparticle studies, and formulation controls.

• Canagliflozin Hemihydrate: Research Workflow

  2026-08-11

  Build reproducible glucose transport and metabolic assays with Canagliflozin hemihydrate, a research-grade SGLT2 inhibitor suited to renal and diabetes mellitus research. A parallel yeast mTOR workflow helps distinguish glucose-transporter biology from nonspecific TOR-pathway effects.

• Trichostatin A (TSA) for Reliable Cell Assays

  2026-08-10

  Learn how Trichostatin A (TSA), SKU A8183, can improve the interpretation and reproducibility of cell viability, proliferation, and cytotoxicity experiments. This scenario-based guide covers mechanism, solvent compatibility, concentration selection, data interpretation, and practical vendor evaluation.

• Morin and the Energy Logic of Podocyte Protection

  2026-08-09

  Morin is emerging as more than a generic antioxidant: recent work links its protective effects in fructose-stressed podocytes to adenosine 5′-monophosphate deaminase activity and mitochondrial energy metabolism. This article translates that mechanism into practical assay strategy and translational decision-making.

• EZH2 Inhibition in HPV-Associated Cervical Cancer

  2026-08-07

  The reference study evaluates EPZ6438 and ZLD1039 as pharmacological strategies for suppressing HPV-associated cervical cancer, combining proliferation, apoptosis, cell-cycle, gene-expression, and preliminary in vivo readouts. Its main contribution is linking EZH2 inhibition with reduced HPV16 E6/E7 expression, restoration of p53 and Rb-associated tumor-suppressive signals, and epithelial marker expression, while identifying stronger activity of EPZ6438 in HPV-positive models.

• BET Bromodomain Inhibitor, (+)-JQ1: Optimizing Translational

  2026-08-07

  Bromodomain Inhibitor, (+)-JQ1 empowers researchers to dissect epigenetic regulation, apoptosis, and inflammation with precision, thanks to its potent and selective BET inhibition. This article delivers actionable workflows, troubleshooting, and the latest synergy insights for translational and disease-modeling applications.

• Topotecan as a Novel Topoisomerase I Inhibitor: Clinical Ins

  2026-08-06

  This review highlights the pharmacological innovation of topotecan, a water-soluble camptothecin analogue, as a topoisomerase I inhibitor with demonstrated clinical efficacy in solid tumors. The article discusses its unique mechanism, pharmacokinetics, toxicity profile, and implications for combination chemotherapy, particularly in comparison to established agents such as etoposide.

• Sumatriptan Succinate: Metabolic Pathways and Inflammation I

  2026-08-06

  Explore the advanced metabolism and anti-inflammatory mechanisms of Sumatriptan Succinate, a leading 5-HT1 receptor agonist. This article uncovers new experimental considerations crucial for migraine research, differentiating itself from standard protocol guides.

• MCL-1 Inhibitor A-1210477: Precision Tools for Cancer Apopto

  2026-08-05

  This article explores the mechanistic, experimental, and translational value of the MCL-1 inhibitor A-1210477, offering strategic guidance for researchers aiming to dissect cancer cell survival pathways. Blending evidence-based insights with practical workflow advice, it clarifies how selective MCL-1 inhibition can transform apoptosis research and the rational design of targeted cancer therapies.

8668 records 8/578 page Previous Next First page 上5页 678910 下5页 Last page